Recurrence of Solid Pseudopapillary Neoplasms of the Pancreas: Results of a Nationwide Study of Risk Factors and Treatment Modalities

Sabine Irtan, Louise Galmiche-Rolland, Caroline Elie, Daniel Orbach, Alain Sauvanet, Dominique Elias, Florent Guérin, Carole Coze, Cécile Faure-Conter, François Becmeur, et al.

► To cite this version:

Sabine Irtan, Louise Galmiche-Rolland, Caroline Elie, Daniel Orbach, Alain Sauvanet, et al.. Recurrence of Solid Pseudopapillary Neoplasms of the Pancreas: Results of a Nationwide Study of Risk Factors and Treatment Modalities. *Pediatric Blood and Cancer*, 2016, 10.1002/pbc.25986 . hal-01327306

HAL Id: hal-01327306

<https://hal.sorbonne-universite.fr/hal-01327306>

Submitted on 6 Jun 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Recurrence of solid pseudopapillary neoplasms of the pancreas: results of a nationwide study
2 of risk factors and treatment modalities

3 S. Irtan¹, MD, PhD, L. Galmiche-Rolland², MD, PhD, C. Elie³, MD, PhD, D. Orbach⁴, MD,
4 A. Sauvanet⁵, MD, PhD, D. Elias⁶, MD, PhD, F. Guérin⁷, MD, PhD, C. Coze⁸, MD, PhD, C.
5 Faure-Contier⁹, MD, F. Becmeur¹⁰, MD, PhD, M. Demarche¹¹, MD, R.B.Galifer¹², MD, PhD,
6 M.A. Galloy¹³, MD, G. Podevin¹⁴, MD, PhD, D. Aubert¹⁵, MD, PhD, C. Piolat¹⁶, MD, PhD,
7 P. De Lagausie¹⁷, MD, PhD, S. Sarnacki¹, MD, PhD.

8 1. Department of Pediatric Surgery, Necker Enfants-Malades Hospital - Université Paris
9 Descartes, Sorbonne Paris Cite, Paris, France.

10 2. Department of Pathology, Necker Enfants-Malades Hospital - Université Paris
11 Descartes, Sorbonne Paris Cite, Paris, France.

12 3. Clinical Research Unit / Clinical Investigation Centre, Necker Enfants-Malades
13 Hospital, Paris, France.

14 4. Department of Pediatrics, adolescents, young adults, Institut Curie, Paris, France -
15 Groupe Fracture, French rare pediatric tumors group.

16 5. Department of Hepato-Pancreato-Biliary Surgery - Pôle des Maladies de l'Appareil
17 Digestif (PMAD), AP-HP, hôpital Beaujon, Clichy, France.

18 6. Department of Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

19 7. Department of Pediatric Surgery, Hôpitaux universitaires Paris-Sud, Bicêtre Hospital,
20 Université Paris XI, Le Kremlin-Bicêtre, France.

21 8. Department of Pediatric Hematology-Oncology, Aix-Marseille Univ and APHM,
22 Hôpital d' Enfants de La Timone, Marseille, France.

9. Department of Pediatrics, Institut Leon Bérard, Lyon, France.
10. Department of Pediatric Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
11. Department of Pediatric Surgery, CHR de la Citadelle, Liège, Belgium.
12. Department of Pediatric Surgery, Lapeyronie-Arnaud de Villeneuve Hospital, Montpellier, France.
13. Department of Pediatric Surgery, Children's Hospital Nancy-Brabois University Hospital, Vandoeuvre-lès-Nancy, France.
14. Department of Pediatric Surgery, University Hospital, Angers, France.
15. Department of Pediatric Surgery, University Hospital, Besançon, France.
16. Department of Pediatric Surgery, University Hospital, Grenoble, France.
17. Department of Pediatric Surgery, Aix-Marseille Univ and APHM, Hôpital d'Enfants de La Timone, Marseille, France.

Corresponding author:

Sabine Irtan, MD, PhD, Service de Chirurgie Pédiatrique Viscérale - Sorbonnes Universités, UPMC Univ Paris 06, Hôpital Trousseau, Assistance Publique Hôpitaux de Paris, 26, avenue Dr Arnold Netter, 75012 PARIS, France. Phone: +33 1 71 73 87 98 ; Fax: +33 1 44 73 69 79, Email: sabine.irtan@gmail.com

Abstract word count: 249

44 Text word count: 2404

45 Brief running title: Risk factors for SPPN recurrence.

46 Keywords: solid pseudopapillary tumor, pancreas, recurrence, survival, pediatric.

47 Figures: 2

48 Tables: 3

49 Supplemental files: 2

Abbreviations	
SPPN	Solid pseudopapillary neoplasms of the pancreas
GCPOT	Group of Pediatric Surgeons Operating on Tumors
WHO	World Health Organization
HIPEC	hyperthermic intraperitoneal chemotherapy

50

51

52

53

54

55

56

57

58

59

Conflict of interest Statement

Dr S Irtan, Dr L. Galmiche-Rolland, Dr C. Elie, Dr D. Orbach, MD, Pr A. Sauvanet, Dr D. Elias, Dr F. Guérin, Dr C. Coze, Dr C. Faure-Conter, Pr F. Becmeur, Dr M. Demarche, Pr R.B.Galifer, Dr M.A. Galloy, Pr G. Podevin, Pr D. Aubert, Pr C. Piolat, Pr P. De Lagausie and Pr S. Sarnacki have no conflicts of interest or financial ties to disclose.

Abstract

Background: Solid pseudopapillary neoplasms of the pancreas (SPPN) can relapse very late, but little is known of risk factors for recurrence and of optimal treatment. We aimed to identify risk factors for recurrence and to analyze treatment modalities in all French pediatric cases of SPPN over the past 20 years.

Material and methods: Data were collected from pediatric oncologists and surgeons, and also from adult pancreatic surgeons in order to identify late recurrences.

Results: Fifty-one patients (41 girls) were identified. Median age at diagnosis was 13.1 years [8.7-17.9]. Abdominal pain was the commonest presenting symptom (32/49, 65%). The tumor was located in the pancreatic head in 24 patients (47%). Preoperative biopsy or cytology was performed in 14 cases (28%). All patients were operated on, a median of 23 days [0-163] after diagnosis. The rate of postoperative morbidity was 29%. With a median follow-up of 65 months [0.3-221], the overall and event-free survival was 100% and 71% respectively. Seven patients (13.7%) relapsed, a median of 43 months [33-94] after initial surgery. Six were treated surgically, either alone (n=3), or with perioperative chemotherapy (n=2) or hyperthermic intraperitoneal chemotherapy (n=1). One patient in whom further treatment was not feasible was still alive at last news. Risk factors for recurrence were positive surgical margins ($p=0.03$) and age less than 13.5 years at diagnosis ($p=0.03$).

Conclusion: SPPN recurrence in this pediatric series was a rare and late event that did not undermine overall survival. Complete surgical removal of recurrent tumors appears to be the best option.

Introduction

Originally described by Frantz in 1959 [1], solid pseudopapillary neoplasms of the pancreas (SPPN) took their definitive name from the last World Health Organization histologic classification of pancreatic tumors in 1996 [2]. Representing up to 1-2% of all exocrine pancreatic tumors in adults and 8-17% of pancreatic tumors in children, SPPN occurs mainly in females at an average age of 22 years, and is symptomatic in up to 80% cases [3]. The pathogenetic mechanisms are unknown. An origin from quiescent pancreatic stem cells (deregulation of the β catenin signaling pathway with overexpression of Sox 9 and PDX1) [4] or from ovarian tissue [5] has been suggested. Abnormal nuclear accumulation of β catenin (shown by immunohistochemistry) and associated point mutations within exon 3 of the *CTNNB1* gene, suggest a role of the Wnt signaling pathway [6,7]. The treatment of choice is complete surgical resection alone, as SPPN is considered to have low malignant potential (estimated doubling time 765 days) [8,9]. Recurrences have been reported up to 19 years after initial surgical resection [10], and there is no consensus on their management. In this French nationwide study, we collected pediatric cases of SPPN diagnosed over the past 20 years in order to study risk factors for recurrence and its treatment.

Patients and methods

In an attempt to identify all pediatric cases of SPPN diagnosed in France over the past 20 years and because no registry existed, we e-mailed all members of the Group of Pediatric Surgeons Operating on Tumors (GCPOT), which comprises all French surgeons involved in the treatment of pediatric tumors, including pancreatic tumors. Eighteen (66%) of the 27 centers contacted responded, of which 12 declared at least one patient (range 1 to 11) corresponding to our search criteria, for a total of 42 patients.

We also contacted adult surgeons involved in pancreatic surgery in all French University hospitals to determine if they had managed patients operated on for a SPPN in childhood or adolescence and who had relapsed in adulthood: 13 of the 25 surgeons contacted by email responded, of whom two declared relevant cases. In addition, one center had operated on seven adolescents (<18 y), who were added to the pediatric series.

In total, we collected data on 51 patients, of whom 16 have already been described in case reports or short series [11-15]. The data collected included demographic features (age at diagnosis, presenting signs and symptoms such as abdominal pain/trauma/mass, pancreatitis, and other incidental findings), biological and radiological characteristics (tumor size and location, homogeneity or heterogeneity, dilatation of the main pancreatic duct or common bile duct, invasion of adjacent organs, venous thrombosis), preoperative biopsy (percutaneous fine-needle aspiration or surgical biopsy), treatment modalities, postoperative morbidity, pathologic analysis of the specimen (presence of a capsule, resection margins, neural or vascular invasion, necrosis or lymphadenopathy, signs of tumor rupture) and survival. All the pathology reports were reviewed by a senior pathologist (LGR). If a recurrence was identified, we collected data on its diagnosis, treatment and outcome.

Statistical Analysis

R software (<http://cran.r-project.org/>) was used for all analyses. Quantitative data are expressed as mean ($\pm$ SD) or median (range) and qualitative data as numbers or percentages. Follow-up was calculated from the date of surgery to the date of relapse or last follow-up. Survival was analyzed with the Kaplan-Meier method. Risk factors for recurrence were identified using the log-rank test for categorical variables and a Cox model for continuous variables.

Results

General features

The clinical features of the entire cohort are listed in Table I. Males and females were equally distributed according to age at diagnosis (Figure 1). The main presenting symptom was abdominal pain (n=32/49, 65%), associated with an abdominal mass (n=3) or abdominal trauma (n=3); other diagnostic circumstances included isolated abdominal trauma (n=4, 8%), isolated pancreatitis (n=3, 6%), or an isolated painless abdominal mass (n=2, 4%). The diagnostic circumstances were fortuitous in 5 patients (10%), unknown in 2 patients, and unusual in 3 patients (6%: jaundice and pruritus; hemorrhagic ulcer; or upper gastrointestinal bleeding revealing esophageal and gastric varices related to portal hypertension secondary to biliary cirrhosis due to common bile duct compression by the tumor) [12]. None of the patients had metastases or local tumor dissemination at initial diagnosis.

The tumors were mainly heterogeneous and located in the head of the pancreas (Table I). The median tumor size (longest axis) was 70 mm [20-180]. Extension to adjacent organs was observed in 3 patients (pancreato-splenic ligament in one case, and transverse mesocolon in two cases). Five patients had peritoneal effusion at diagnosis; one patient with hemoperitoneum had no malignant cells on cytology. No tumor rupture was seen on imaging studies.

Preoperative biopsy was performed by percutaneous fine needle aspiration in 10 patients (20%) and by laparoscopy in 2 patients. Per surgical frozen section was performed in 14 cases.

Treatment modalities and histologic characteristics of the resected specimen

All the patients underwent surgery, a median of 23 days [0-163] after diagnosis based on imaging or biopsy (Table II). Tumor resection was combined with cholecystectomy (n = 6), appendectomy (n = 4), colectomy (n=2), vascular suture (n=2), splenectomy (n=1), partial gastrectomy (n = 1) or jejunostomy (n = 1). The tumor was resected by laparoscopy in two cases.

Postoperative morbidity occurred in 29% of patients, a median of 13 days [4-83] after surgery (Table II). The main postoperative complication was pancreatic fistula (n=4), that resolved spontaneously in two cases and necessitated re-operation in one case (because of associated biliary leakage) and per-endoscopic drainage in another case.

One patient developed a seroma 4 years after surgery and underwent further surgery because of suspected recurrence. Two patients developed pseudocysts, 6 and 18 months after surgery, which resolved spontaneously in one case and was surgically drained in the other case. One patient developed left hepatic artery thrombosis after initial resection and underwent multiple surgeries for severe postoperative complications [11]. The patient with biliary cirrhosis underwent liver transplantation 7 years 8 months after tumor surgery [12].

Histologic analysis revealed a capsule in more than 80% of cases, and capsule invasion in half these cases. Signs of malignancy, as defined by the 2010 World Health Organization (WHO) classification, including vascular, perineural or peripancreatic tissue invasion, were present in 22 patients (43.1%): 16 patients had one criterion, five 2 criteria and one all 3 criteria (Table I).

Risk factors for relapse and treatment modalities

The overall and event-free survival rates at 15 years were respectively 100% and 71% [53-94] (Figure 2A). Seven patients (13.7%) relapsed, a median of 41.8 months after initial surgery [33-94]. One patient experienced two relapses at a 10.6-month interval. During a median follow-up of 65 months [0.3-221], recurrences were found in 5 patients by routine follow-up imaging (CT or MRI), by the occurrence of hypogastric pain in one patient, and by self-examination (mass) in one patient. The relapse was localized to the pancreas in two patients and disseminated to the whole peritoneum in the other five patients. One patient had chest nodules. The patients who relapsed had been diagnosed at a maximum age of 13.1 years, and all three patients diagnosed before the age of 10 years relapsed. Age at diagnosis was unknown in one patient who relapsed. The only significant risk factors for relapse were age under 13.5 years at diagnosis ($p=0.03$) (Figure 2B) and positive surgical margins at initial tumor resection ($p=0.03$) (Figure 2C). No significant influence of tumor size, tumor location, tumor rupture, percutaneous or surgical preoperative biopsy, vascular or peripancreatic tissue invasion was found (Table III).

At relapse, six patients underwent cytoreductive surgery, either alone ($n=3$) or with hyperthermic intraperitoneal chemotherapy (HIPEC) ($n=1$), pre-operative chemotherapy (four cycles of 5-FU - oxaliplatin – irinotecan, $n=1$) or postoperative chemotherapy (six cycles of 5-FU - oxaliplatin – irinotecan, $n=1$). The patient who received preoperative chemotherapy had stable disease at time of surgery and persistent chest nodules at the end of chemotherapy; these were carefully monitored and remained stable. In the last patient, the tumor recurred 3 years after initial surgery (subtotal resection) and invaded the head of the pancreas and the hepatic pedicle up to the gallbladder. Radical surgery with extensive pancreatic resection and liver transplantation was considered too risky and no treatment was delivered, but the patient was alive 20 months later.

Discussion

Published pediatric series of SPPN tumors are rare and small [8, 16-32], the largest including 45 patients aged from 9 to 20 years [32]. As no registry exists for this specific tumor in our country, we conducted the survey by emailing our colleagues, pediatric surgeons but also adult ones to retrieve late recurrences of patients operating during childhood. Although only 66% of French pediatric centers responded to our survey, we were able to collect data on 51 patients. Because of the specificities of pancreatic surgery, some adolescents were managed by adult surgeons, as in the majority of published series. Few previous studies of SPPN have separately analyzed adults and children [19]. The main features of SPPN in children are a higher frequency of abdominal pain [8,18,25,30,32] and fewer incidental diagnoses (22%) [19,33]. An exhaustive review of the literature shows that SPPN are equally distributed in the head, body and tail of the pancreas, and have a mean size of 7 cm (Supplemental Table I). Outcome is reported to be excellent, with an estimated recurrence rate of about 5.5%, comparing favorably with that in adults [3].

Clinical and pathological factors found to be predictive of recurrence in adult series or combined adult and pediatric series include male gender [34], younger age [19,35], abdominal injury or rupture [13,36,37], large tumor size [33,38] and microscopic features of malignancy such as vascular, perineural and peripancreatic tissue invasion [33,39,40]. Patients with metastases at diagnosis tend to be older [35,36,41] and are at a higher risk of recurrence and death [39,40].

In our series, the only two significant risk factors for relapse were age under 13.5 years at diagnosis and positive surgical margins after initial tumor resection. No significant influence of tumor size, tumor location, tumor rupture, percutaneous or surgical preoperative biopsy, and vascular or peripancreatic tissue invasion was noted.

The influence of young age at diagnosis in SPPN recurrence is in keeping with previous reports on patients treated for localized SPPN during childhood (Supplemental Table I). The explanation for this remains unclear. This may be due to a specific tumor biology according to age. In a previous analysis, we identified PDX1 and Sox9 proteins expression in the cytoplasmic compartment of SPPN, favoring the hypothesis that SPPN originated from transformation of quiescent pancreatic stem cells [4]. Analysis of genetic alterations by array comparative genomic hybridization reported several chromosomal abnormalities, such as 13q, 17q, 1q and 8q gains that positively correlated with more aggressive histologic feature of the tumor [42]. On the contrary, immunohistochemistry failed to demonstrate a link between the expression of MMP-7, cyclin-D1, c-myc, and Ki-67 and the potential malignancy of SPPN [43]. Central review of all specimen and analysis of molecular markers that could correlate with the aggressive behaviour was unfortunately not possible in the present series because of its retrospective, multicentric and long-term nature.

Despite this limitation, we studied the presence of signs of malignancy, as perineural, peripancreatic or vascular invasion [26,30,44], which were recently reported to be a major risk factor for relapse in adults. These features were found to be an independent predictor of tumor relapse in multivariable analysis of a large multicenter cohort [33]. We found no histologic features predictive of recurrence, except for microscopically positive margins, which were found ten times more often in patients who relapsed.

There are few published data on the influence of positive margins [25], although complete surgical excision has always been recommended [3]. Different types of pancreatic resection are used according to the tumor location. In order to preserve long-term pancreatic exocrine and endocrine functions, enucleation was used in 13.7% of our patients, as compared to 8.2% overall in pediatric series (Supplemental Table II) and 4.7% in adults [3]. The high rate of conservative surgery could not be related to a younger age at surgery but might explain the

high frequency of microscopically positive margins in our patients who relapsed (60%). Postoperative complications, mainly related to pancreaticoduodenectomy and spleen-preserving distal pancreatectomy, occurred in 25% of our patients but are reported in up to 50% of cases after minimally invasive surgery [30]. Interestingly, none of our patients with postoperative complications relapsed.

Abdominal blunt injury has been incriminated in tumor spread at initial diagnosis [36,37], and laparoscopic biopsy was held responsible for peritoneal recurrence in the first report of laparoscopic management of SPPN [13]. Later studies supported the safety both of percutaneous needle aspiration [15,18] and of laparoscopy for the diagnosis and treatment of SPPN [29,30]. In our series, we found no significant influence of laparoscopy or tumor rupture, either pre- or peri-operatively, on the risk of relapse.

SPPN recurrences tended to occur late, up to 95 months after initial diagnosis in our series and 14 years in the literature, calling for very long-term follow-up [10]. Contrary to initial treatment, there is no consensus on the treatment of recurrences. Repeat resection of peritoneal seeding has been widely used, with good outcomes, even in case of incomplete removal (Supplemental Table I) [45,46]. Radiofrequency ablation seems the best option if liver metastases are not easily resectable (Supplemental Table I) [10,32,35]. The use of hyperthermic intraperitoneal chemotherapy has only been reported once in this setting [47]. The rationale for using this demanding surgical technique was that the tumor recurrences were often confined to the peritoneum and that systemic chemotherapy is ineffective, despite reported relapsed tumor shrinkage with etoposide-ifosfamide-cisplatin [16] or 5FU-cisplatin [48]. It remains to be seen whether this innovative technology has a place in the treatment of recurrent SPPN [49].

Conclusion

This large pediatric series confirmed that resection of SPPN in the pediatric population should be complete, even if it implies heavy surgery and reconstruction procedures. Microscopic malignant features were not associated with recurrence but should certainly be taken in account in individual patient management. Contrary to previous reports, tumor rupture did not seem to be deleterious, and laparoscopy did not appear to be contraindicated, when it allowed microscopically complete resection.

The complexity of this rare surgery in children and the need for long-term postoperative follow-up necessitate close collaboration between pediatric and adult teams. The high risk of recurrence observed in younger children is still not understood and underlines the need for further molecular analysis taking into account the potential developmental aspect of this pancreatic tumor.

References

1. Frantz KZ. Tumors of the pancreas: Atlas of tumor pathology. Washington DC, US Armed Force Institute of Pathology, 1959:32-33.
2. Kloppel G, Solcia E, Longnecker DS. Histological typing of tumors of the exocrine pancreas. 2nd ed. (WHO international histological classification of tumors). Berlin, Heidelberg, New York: Springer; 1996.
3. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. *J Am Coll Surg* 2005; 200: 965-72.
4. Galmiche L, Sarnacki S, Verkarre V, Boizet B, Duvillie B, Fabre M, Jaubert F. Transcription factors involved in pancreas development are expressed in paediatric solid pseudopapillary tumours. *Histopathology*. 2008;53:318-24.
5. Kosmahl M, Seada LS, Jänig U, Harms D, Klöppel G. Solid-pseudopapillary tumor of the pancreas: its origin revisited. *Virchows Arch*. 2000;436:473-80.
6. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, Cameron JL, Wu TT, Hruban RH. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. *Am J Pathol*. 2002;160:1361–1369.
7. Tanaka Y, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, Nagahara N, Sasaki F, Kitagawa N, Nakatani Y, Kobayashi Y. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solidpseudopapillary neoplasm. *Cancer Res*. 2001;61:8401–8404.
8. Ky A, Shilyansky J, Gerstle J, Taylor G, Filler RM, Grace N, Superina R. Experience with papillary and solid epithelial neoplasms of the pancreas in children. *J Pediatr Surg*. 1998;33:42-4.

9. Kato T, Egawa N, Kamisura T, Tu Y, Sanaka M, Sakaki N. A case of solid pseudopapillary neoplasm of the pancreas and tumor doubling time. *Pancreatology* 2002;2: 495-8.
10. Huang HL, Shih SC, Chang WH, Wang TE, Chen MJ, Chan YJ. Solid-pseudopapillary tumor of the pancreas: clinical experience and literature review. *World J Gastroenterol.* 2005 ;11:1403-9.
11. Campanile M, Nicolas A, LeBel S, Delarue A, Guys JM, de Lagausie P. Frantz's tumor: is mutilating surgery always justified in young patients? *Surg Oncol.* 2011;20:121-5.
12. Denis MA, Frère A, Brixko C, Dresse D, Denoël A, Demarche M, Defrère P, Lismonde JL, Fridman V, Deflandre J. Pseudopapillary tumor of the pancreas revealed by rupture of esophageal and gastric varices secondary to biliary cirrhosis due to bile duct compression. *Gastroenterol Clin Biol.* 2005;29:291-3.
13. Fais PO, Carricaburu E, Sarnacki S, Berrebi D, Orbach D, Baudoin V, de Lagausie P. Is laparoscopic management suitable for solid pseudo-papillary tumors of the pancreas. *Pediatr Sur Int* 2009;25:617-21.
14. Muller CO, Guérin F, Goldzmidt D, Fouquet V, Franchi-Abella S, Fabre M, Branchereau S, Martelli H, Gauthier F. Pancreatic resections for solid or cystic pancreatic masses in children. *J Pediatr Gastroenterol Nutr.* 2012;54:369-73
15. Tlili Y, Lemaistre AI, Dubois R, Faure-Contier C. Percutaneous cytologic diagnosis of solid pseudopapillary tumors of the pancreas in children. *J Pediatr Hematol Oncol.* 2013;35:90-2.
16. Rebhandl W, Felberbauer FX, Puig S, Paya K, Hochschorner S, Barlan M, Horcher E. Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature. *J Surg Oncol.* 2001;76: 289-96.

17. Shorter NA, Glick RD, Klimstra DS, Brennan MF, Laquaglia MP. Malignant pancreatic tumors in childhood and adolescence: The Memorial Sloan-Kettering experience, 1967 to present. *J Pediatr Surg.* 2002;37:887-92.
18. Choi SH, Kim SM, Oh JT, Park JY, Seo JM, Lee SK. Solid pseudopapillary tumor of the pancreas: a multicenter study of 23 pediatric cases. *J Pediatr Surg.* 2006;41:1992-5.
19. Lee SE, Jang JY, Hwang DW, Park KW, Kim SW. Clinical features and outcome of solid pseudopapillary neoplasm: differences between adults and children. *Arch Surg.* 2008;143:1218-21.
20. Perez EA, Gutierrez JC, Koniaris LG, Neville HL, Thompson WR, Sola JE. Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients. *J Pediatr Surg.* 2009;44:197-203.
21. Yu DC, Kozakewich HP, Perez-Atayde AR, Shamberger RC, Weldon CB. Childhood pancreatic tumors: a single institution experience. *J Pediatr Surg.* 2009;44:2267-72.
22. Dall'igna P, Cecchetto G, Bisogno G, Conte M, Chiesa PL, D'Angelo P, De Leonardis F, De Salvo G, Favini F, Ferrari A; TREP Group. Pancreatic tumors in children and adolescents: the Italian TREP project experience. *Pediatr Blood Cancer.* 2010;54:675-80.
23. Sugito K, Kusafuka T, Hoshino M, Inoue M, Ikeda T, Hagiwara N, Koshinaga T, Shichino H, Chin M, Mugishima H. Application of radiofrequency ablation for giant solid pseudopapillary tumor of the pancreas. *Pediatr Int.* 2010;52:e29-31.
24. Zampieri N, Schiavo N, Capelli P, Scarpa A, Bassi C, Camoglio FS. Pseudopapillary tumor in pediatric age: clinical and surgical management. *Pediatr Surg Int.* 2011;27:1271-5.

25. Speer AL, Barthel ER, Patel MM, Grikscheit TC. Solid pseudopapillary tumor of the pancreas: a single-institution 20-year series of pediatric patients. *J Pediatr Surg.* 2012;47:1217-22.
26. van den Akker M, Angelini P, Taylor G, Chami R, Gerstle JT, Gupta A. Malignant pancreatic tumors in children: a single-institution series. *J Pediatr Surg.* 2012;47:681-7.
27. Rojas Y, Warneke CL, Dhamne CA, Tsao K, Nuchtern JG, Lally KP, Vasudevan SA, Hayes-Jordan AA, Cass DL, Herzog CE, Hicks MJ, Kim ES, Austin MT. Primary malignant pancreatic neoplasms in children and adolescents: a 20 year experience. *J Pediatr Surg.* 2012;47:2199-204.
28. Morita K, Urushihara N, Fukumoto K, Miyano G, Yamoto M, Nouso H, Miyake H, Kaneshiro M. Solid pseudopapillary tumor of the pancreas in children: surgical intervention strategies based on pathological findings. *Pediatr Surg Int.* 2014;30:253-7.
29. Petrosyan M, Franklin AL, Jackson HT, McGue S, Reyes CA, Kane TD. Solid pancreatic pseudopapillary tumor managed laparoscopically in adolescents: a case series and review of the literature. *J Laparoendosc Adv Surg Tech A.* 2014;24:440-4.
30. Namgoong JM, Kim DY, Kim SC, Kim SC, Hwang JH, Song KB. Laparoscopic distal pancreatectomy to treat solid pseudopapillary tumors in children: transition from open to laparoscopic approaches in suitable cases. *Pediatr Surg Int.* 2014;30:259-66.
31. Park JY, Kim SG, Park J. Solid pseudopapillary tumor of the pancreas in children: 15-year experience at a single institution with assays using an immunohistochemical panel. *Ann Surg Treat Res.* 2014;86:130-5.

32. Hwang J, Kim DY, Kim SC, Namgoong JM, Hong SM. Solid-pseudopapillary neoplasm of the pancreas in children: can we predict malignancy? *J Pediatr Surg.* 2014;49:1730-3.
33. Kang CM, Choi SH, Kim SC, Lee WJ, Choi DW, Kim SW; Korean Pancreatic Surgery Club. Predicting recurrence of pancreatic solid pseudopapillary tumors after surgical resection: a multicenter analysis in Korea. *Ann Surg.* 2014;260:348-55.
34. Machado MC, Machado MA, Bacchella T, Jukemura J, Almeida JL, Cunha JE. Solid pseudopapillary neoplasm of the pancreas: distinct patterns of onset, diagnosis, and prognosis for male versus female patients. *Surgery.* 2008;143:29–34.
35. Kim CW, Han DJ, Kim J, Kim YH, Park JB, Kim SC. Solid pseudopapillary tumor of the pancreas: can malignancy be predicted? *Surgery.* 2011;149:625-34.
36. Lévy P, Bougaran J, Gayet B. Diffuse peritoneal carcinosis of pseudo-papillary and solid tumor of the pancreas. Role of abdominal injury. *Gastroenterol Clin Biol.* 1997;21:789-93.
37. Tajima Y, Kohara N, Maeda J, Inoue K, Kitasato A, Natsuda K, Irie J, Adachi T, Kuroki T, Eguchi S, Kanematsu T. Peritoneal and nodal recurrence 7 years after the excision of a ruptured solid pseudopapillary neoplasm of the pancreas: report of a case. *Surg Today.* 2012;42:776-80.
38. Butte JM, Brennan MF, Gönen M, Tang LH, D'Angelica MI, Fong Y, Dematteo RP, Jarnagin WR, Allen PJ. Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. *J Gastrointest Surg.* 2011;15:350–357.
39. Estrella JS, Li L, Rashid A, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. *Am J Surg Pathol.* 2014;38:147-57.

40. Serrano PE, Serra S, Al-Ali H, Gallinger S, Greig PD, McGilvray ID, Moulton CA, Wei AC, Cleary SP. Risk factors associated with recurrence in patients with solid pseudopapillary tumors of the pancreas. *JOP*. 2014 28;15:561-8.
41. Sumida W, Kaneko K, Tainaka T, Ono Y, Kiuchi T, Ando H. Liver transplantation for multiple liver metastases from solid pseudopapillary tumor of the pancreas. *J Pediatr Surg*. 2007;42:e27-31.
42. Rund CR, Moser AJ, Lee KK, Zeh HJ, Teot LA, Dacic S, Krasinskas AM. Array comparative genomic hybridization analysis of solid pseudopapillary neoplasms of the pancreas. *Mod Pathol*. 2008;21:559-64.
43. Kang CM, Kim HK, Kim H, Choi GH, Kim KS, Choi JS, Lee WJ. Expression of Wnt target genes in solid pseudopapillary tumor of the pancreas: a pilot study. *Pancreas*. 2009;38:e53-9.
44. Nishihara K, Nagoshi M, Tsuneyoshi M, Yamaguchi K, Hayashi I. Papillary cystic tumors of the pancreas. *Cancer* 1993; 71:82-92.
45. Andronikou S, Moon A, Ussher R. Peritoneal metastatic disease in a child after excision of a solid pseudopapillary tumour of the pancreas: a unique case. *Pediatr Radiol*. 2003; 33:269-71.
46. Horisawa M, Niinomi N, Sato T, Yokkoi S, Oda K, Ichikawa M. Frantz tumor (solid and cystic tumor of the pancreas) with liver metastasis: successful treatment and long-term follow up. *J Pediatr Surg*. 1995;30: 724-6.
47. Honore C, Goere D, Dartigues P, Burtin P, Dumont F, Elias D. Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz's tumour) of the pancreas treated with HIPEC. *Anticancer Res*. 2012;32:1069-73.
48. Soloni P, Cecchetto G, Dall'igna P, Carli M, Toffolutti T, Bisogno G. Management of unresectable solid papillary cystic tumor of the pancreas. A case report and literature review. *J Pediatr Surg*. 2010;45:e1-6.

49. Hayes-Jordan A, Green H, Lin H, Owusu-Agyemang P, Mejia R, Okhuysen-Cawley R, Cortes J, Fitzgerald NE, McAleer MF, Herzog C, Huh WW, Anderson P. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Children, Adolescents, and Young Adults: The First 50 Cases. *Ann Surg Oncol*. 2015;22:1726-32.
50. Lack EE, Cassady JR, Levey R, Vawter GF. Tumours of the exocrine pancreas in children and adolescents: a clinical and pathologic study of eight cases. *Am J Surg Pathol* 1983;7:319-27.
51. Cubilla AL, Fitzgerald PJ. Tumors of the exocrine pancreas. In: *Atlas of tumor pathology fascicle*. Washington, DC: US Armed Forces Institute of Pathology; 1982:19.

Figure Legends

Figure 1: Age distribution according to gender.

Figure 2: Disease-free survival (A) of the entire cohort with the confidence interval; (B) according to age at diagnosis; and (C) according to surgical margin status.

Table legends

Table I. Clinical, radiological and histological characteristics.

Table II. Type of surgery and related morbidity for the management of primary tumor.

Table III. Differences between disease-free and recurrent SPPN.

Supplemental Table I. Details of treatment for recurrent SPPN in the literature.

Supplemental Table II. Specific pediatric series of primary SPPN highlighting the clinical features, treatment modalities and outcome.

Fig. 1

Fig. 2

B

C

Table I. Clinical, radiological and histological characteristics

Clinical Features		Frequency, %, median [range]
Sex		
	<i>Male</i>	10/50 (22%)
	<i>Female</i>	41/50 (78%)
Age, year		13.1 [8.7-17.9]
Symptoms		
	<i>Yes</i>	45/49 (88%)
	<i>No</i>	6/49 (12%)
Radiological Features		
Location		
	<i>Head</i>	24 (47%)
	<i>Isthmus</i>	2 (4%)
	<i>Body</i>	8 (16%)
	<i>Tail</i>	17 (33%)
Radiological appearance		
	<i>Heterogeneity</i>	44 (86%)
	<i>Solid</i>	5 (10%)
	<i>Homogeneity</i>	1 (2%)
	<i>Hypodensity</i>	1 (2%)
Tumor size, mm		70 [20-120]
Abdominal effusion		5/50 (10%)
Dilatation of main pancreatic duct		9/50 (18%)
Dilatation of common bile duct		3/50 (6%)
Pathological features		
Presence of capsule		42/50 (84%)
Capsule invasion		21 (50%)
Vascular invasion		8/50 (16%)
Perineural invasion		12 (24%)
Peripancreatic tissue invasion		7 (14%)
Positive margins		5 (10%)
Lymph nodes metastasis		1 (2%)
Tumor rupture		2 (4%)
Tumor necrosis		11/50 (22%)

Table II. Type of surgery and related morbidity for the management of primary tumor.

Type of Surgery	Nb of patients	Morbidity
Pancreaticoduodenectomy	18 (35%)	Pancreatic fistula (n=1) Pleural effusion (n=1) Delayed gastric emptying (n=1) Stenosis of the pancreatojejunal anastomosis (n=1) Twist of the biliodigestive anastomosis (n=1) Thrombosis of the hepatic artery (n=1)
Central pancreatectomy	6 (12%)	Pancreatic and biliary fistula (n=1)
Distal pancreatectomy + splenectomy	8 (16%)	None
Spleen preserving distal pancreatectomy	12 (23%)	Pancreatic fistula (n=1) Left gastric artery bleeding (n=1) Seroma (n=2)
Tumor enucleation	7 (14%)	Pancreatic fistula (n=1)

Nb Number

Table III. Differences between disease-free and recurrent SPPN.

	Number of subjects	Number of recurrences (%*)	p-value (Log Rank test)
Age, yr**			0.03
<13.5 y	29	6 (39%)	
≥ 13.5 y	20	0 (0%)	
Sex			0.92
Male	10	1 (25%)	
Female	41	6 (29%)	
Clinical features			
Abdominal pain**			0.38
No	17	4 (33%)	
Yes	32	3 (14)	
Abdominal trauma**			0.19
No	42	4 (15%)	
Yes	7	2 (63%)	
Tumor size, mm			0.10
<80	21	3 (19%)	
≥80	13	4 (52%)	
Tumor location			0.33
Head	24	2 (21%)	
Isthmus	2	1 (50%)	
Body	8	0 (0%)	
Tail	17	4 (40%)	
Morbidity			0.07
No	36	7 (39%)	
Yes	15	0 (0%)	
Pathological features			
Presence of capsule***			0.55
No	8	1 (14%)	
Yes	42	6 (34%)	
Capsule invasion***			0.65
No	20	2 (31%)	
Yes	21	3 (35%)	
Vascular invasion***			0.18
No	42	4 (16%)	
Yes	8	2 (0%)	
Perineural invasion			0.74
No	39	5 (30%)	
Yes	12	2 (21%)	
Peripancreatic tissue invasion			0.78

	No	44	6 (32%)	
	Yes	7	1 (17%)	
Positive margins				0.03
	No	46	4 (19%)	
	Yes	5	3 (70%)	
Lymph nodes metastasis				0.55
	No	50	7 (31%)	
	Yes	1	0 (0%)	
Tumor rupture				0.61
	No	49	7 (30%)	
	Yes	2	0 (0%)	
Tumor necrosis				0.20
	No	40	7 (34%)	
	Yes	11	0 (0%)	

*percentage of recurrence is calculated from Kaplan-Meyer estimation for each subgroups (i.e. taking into account censored patients)

** two missing data

*** one missing data